The Veterinary Medicines Directorate has opened applications for a G7 Pharmacovigilance Senior Assessor and Reporting Lead, with the notice published on 18 September 2026 and a closing date of 12 October 2026. The GOV.UK notice lists a salary of £64,015 with pension provision and annual leave starting at 25 days. (gov.uk) Read narrowly, this is a recruitment notice. In regulatory terms, it also points to continued investment in post-authorisation surveillance, the system used to test whether veterinary medicines remain safe and effective once they are in routine use across the UK market. The VMD says the post will support ongoing assessment of the benefit-risk balance of authorised products. (gov.uk)
The VMD, an executive agency of Defra, is responsible for monitoring adverse events, authorising companies to sell veterinary medicines, controlling manufacture and distribution, advising ministers, and enforcing the Veterinary Medicines Regulations. In VMD guidance, pharmacovigilance is defined as the science and activities concerned with detecting, assessing, understanding and preventing adverse effects or other medicine-related problems, and that definition applies equally to veterinary products. (gov.uk) Approval is therefore not the end of scrutiny. The VMD states that medicines are monitored for the rest of their time on the market, with assessment drawing on both quantitative and qualitative methods and reviewed through monthly Signal Detection meetings and regular Benefit-Risk meetings. (gov.uk)
The timing of the vacancy aligns with a larger regulatory shift. The fuller job description says recent amendments to the Veterinary Medicines Regulations 2013 increased pharmacovigilance obligations, prompting expansion and restructuring of the pharmacovigilance team. Separate implementation guidance states that the amended rules took effect on 17 May 2024, while transition arrangements for industry run to 17 May 2027 because full compliance was estimated to require three years. (jobs.service.gov.uk) Those changes matter operationally. VMD guidance confirms the move away from Periodic Safety Update Reports to annual Benefit-Risk Reports, the introduction of signal notifications during the year, and a requirement for UK serious and non-serious adverse event reports to be submitted within 30 days of awareness. Urgent signals that require rapid safety action must be reported within one to three days. (gov.uk)
The scale of surveillance is material. VMD guidance states that the agency receives around 25,000 adverse event reports a year and monitors more than 6,000 authorised veterinary medicinal products. It identifies reports from veterinary professionals, animal owners, farmers and others as the main evidence source, supplemented by post-marketing studies, product defect reports, published literature, regulatory data and submissions from pharmaceutical companies. (gov.uk) Against that workload, the advertised post is not confined to technical review. The full job description says the successful candidate will manage four direct reports, lead horizon scanning and research activity, assess the post-authorisation benefit-risk balance of pharmaceuticals, vaccines and novel therapies, and coordinate reporting and performance monitoring for internal governance and external publication. (jobs.service.gov.uk)
For marketing authorisation holders, the vacancy sits beside a more demanding compliance model. The VMD inspects companies to check they have the personnel, systems and facilities needed to meet pharmacovigilance duties, while guidance allows for requests for closer monitoring, studies, product literature changes and other regulatory action where the benefit-risk balance changes. (gov.uk) For veterinary professionals and animal keepers, the system still depends heavily on reporting. GOV.UK guidance states that anyone can report an adverse event and that good-quality reports strengthen the evidence base used for regulatory decisions. The VMD launched a public adverse event reporting service on 20 May 2026 and an industry pharmacovigilance reporting service on 10 July 2026, showing a broader shift towards digital submission and oversight. (gov.uk)
The vacancy therefore has a direct public-interest dimension. The VMD’s statutory remit covers animal health, public health and the environment, and pharmacovigilance work can lead to updated product literature, urgent safety communications, in-depth assessment findings and inspection activity. Senior assessment capacity is part of how that regulatory system is maintained. (gov.uk) Applications are being taken through Civil Service Jobs, with the GOV.UK notice stating G7 grade, salary of £64,015, pension, leave starting at 25 days and a closing date of 12 October 2026. The wider policy point is the continued build-up of regulatory surveillance after authorisation, when wider use can reveal adverse events and other risks that were not fully apparent before a product reached the market. (gov.uk)